Accordingly, multiple studies have focused on predicting AD pathology using cerebrospinal fluid (CSF) biomarkers, such as phosphorylated-tau, total-tau, and β-amyloid (Aβ), or apolipoprotein E ε4 allele (APOE4) in PD5–7. This evidence concerns the gene APOE and Alzheimer disease.